Mark Feinberg, M.D., Ph.D., is a physician scientist who currently serves as President and CEO of IAVI. At IAVI, he leads a global team working to advance the development of vaccines and other biomedical innovations to protect against infection with HIV, TB, and other infectious diseases that disproportionately impact people living in low- and middle-income countries. IAVI’s mission is to translate scientific discoveries into affordable and globally accessible public health solutions. Prior to joining IAVI in 2015, Feinberg served as chief public health and science officer with Merck Vaccines. In this role, he helped advance the development and global availability of vaccines against rotavirus, human papillomavirus, and other infectious diseases. Previously, he spent more than 20 years exploring HIV/AIDS pathogenesis, treatment, and prevention research and the biology of emerging diseases in both academia and government. Feinberg played a central role in the creation of the Coalition for Epidemic Preparedness Innovations (CEPI) which was established to help better prepare for and respond to emerging infectious disease threats.